Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival

Journal of Neuro-Oncology

Volumn 35, Issue 1, 1997, Pages 13-28

  Rainov, Nikolai G ^a   Dobberstein, Karl Ulrich ^a   Bahn, Hannes ^a   Holzhausen, Hans Jürgen ^a   Lautenschläger, Christine ^a   Heidecke, Volkmar ^a   Burkert, Winfried ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Anaplastic astrocytoma; Epidermal growth factor receptor; Glioblastoma multiforme; Immunohistochemistry; mdm2; Molecular biology; p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; PROTEIN P53;

ADULT; ARTICLE; CANCER SURVIVAL; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

ANALYSIS OF VARIANCE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; ONCOGENES; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0030806772     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005841520514     Document Type: Article

References (118)

1. Burger PC, Green SB: Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59: 1617-1625, 1987
2. Fine HA: The basis for current treatment recommendations for malignant gliomas. J Neurooncol 20: 111-120, 1994
3. Garfield J: Present status and future role of surgery for malignant supratentorial gliomas. Neurosurg Rev 9: 23-25, 1986
4. Shugg D, Allen BJ, Blizzard L, Dwyer T, Roder D: Brain cancer incidence, mortality and case survival: Observations from two Australian cancer registries. Int J Cancer 59: 765-770, 1994
5. Mahaley MS Jr, Mettlin C, Natarajan N, Laws ER Jr, Peace BB : National survey of patterns of care for brain tumor patients. J Neurosurg 71: 826-836, 1989
6. Mbidde EK, Selby PJ, Perren TJ, Dearnaley DP, Whitton A, Ashley S, Workman P, Bloom HJ, McElwain TJ: High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer 58: 779-782, 1988
7. Devaux BC, O'Fallon JR, Kelly PJ: Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78: 767-775, 1993
8. Wong AJ, Zoltick PW, Moscatello DK: The molecular biology and molecular genetics of astrocytic neoplasms. Semin Oncol 21: 139-148, 1994
9. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is in variably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899-6903, 1987
10. Rubio MP, Von Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN: Accumulation of wild type p53 protein in human astrocytoma. Cancer Res 53: 3465-3467, 1993
11. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739, 1993
12. Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH: Alterations of the TP53 gene in human gliomas. Cancer Res 54: 1324-1330, 1994
13. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91: 7727-7731, 1994
14. Montine TJ, Bruner JM, Vandersteenhoven JJ, Dodge RK, Burger PC: Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms. Diagn Mol Pathol 3: 240-245, 1994
15. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson AD : Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66: 373-385, 1992
16. Levine AJ, Momand J, Finlay CA : The p53 tumor suppressor gene. Nature 351: 453-456, 1991
17. Mukhopadhyay T, Maxwell SA, Roth JA: p53 Suppressor Gene. Springer, New York Berlin, 1995, 125 pp.
18. Haapasalo H, Isola J, Sallinen P, Kalimo H, Helin H, Rantala I: Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Pathol 142: 1347-1351, 1993
19. Alderson LM, Castleberg RL, Harsh GR IV, Louis DN, Henson JW: Human gliomas with wild-type p53 express bcl-2. Cancer Res 55: 999-1001, 1995
20. Chen JD, Lin JY, Levine AJ: Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med 1: 142-152, 1995
21. Chen CY, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB: Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 91: 2684-2688, 1994
22. Donehower LA, Bradley A: The tumor suppressor p53. Biochim Biophys Acta 1155: 181-205, 1993
23. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992
24. Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565-1569, 1991
25. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ: Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8: 2353-2360, 1993
26. Zhou MX, Yeager AM, Smith SD, Findley HW: Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 85: 1608-1614, 1995
27. Wiethege T, Voss B, Müller KM: Detection of mdm2-proto-oncogene in parafffin embedded human bronchial epithelium. J Cancer Res Clin Oncol 120: 252-255, 1994
28. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231-2234, 1993
29. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O: MDM2 Gene amplification and transcript levels in human sarcomas: Relationship to TP53 gene status. J Natl Cancer Inst 86: 1297-1302, 1994
30. Bueso-Ramos CE, Yang Y, de Leon E, McCown P, Stass SA, Albitar M: The human MDM-2 oncogene is overexpressed in leukemias. Blood 82: 2617-2623, 1993
31. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, Downward J, Mayes ELV, Whittle N, Waterfield MD, Seeburg PH: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425, 1984
32. Sainsbury JRC, Sherbert GV, Farndon JR, Harris AL: Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1: 364-366, 1985
33. Harris AL, Neal DE: Epidermal growth factor and its receptor in human cancer. In: Sluyser M (ed) Growth Factors and Oncogenes in Breast Cancer. Ellis Horwood Ltd, Chichester, UK, 1987, pp 60-90
34. Neal DE, Marsh C, Bennet MK, Abel PD, Hall RR, Sainsbury JRC, Harris AL: Epidermal growth factor receptor in human bladder cancer: Comparison of invasive and superficial tumours. Lancet 1: 366-368, 1985
35. Gullick WJ, Marsden JJ, Whittle N, Ward B, Bobrow L, Waterfield MD : Expression of epidermal growth factor receptors on human cervical, ovarian, and vulvar carcinomas. Cancer Res 46: 285-292, 1986
36. Gross ME, Zorbas MA, Daniels YJ, Garcia R, Gallick GE, Olive M, Brattain MG, Boman BM, Yeoman LC: Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 51: 1452-1459, 1991
37. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle H, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary brain tumours of glial origin. Nature 313: 144-147, 1985
38. Bigner SH, Wong AJ, Mark J, Muhlbaier LH, Kinzler KW, Vogelstein B, Bigner DD: Relationship between gene amplification and chromosomal deviations in malignant human gliomas. Cancer Genet Cytogenet 9: 165-170, 1987
39. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DD, Vogelstein B: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89: 2965-2969, 1992
40. Fuller GN, Bigner SH: Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat Res 276: 299-306, 1992
41. Chozick BS, Pezzullo JC, Epstein MH, Finch PW: Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35: 831-838, 1994
42. Collins VP: Amplified genes in human gliomas. Semin Cancer Biol 4: 27-32, 1993
43. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318-1327, 1993
44. Kyritsis AP, Saya H: Epidemiology, cytogenetics, and molecular biology of brain tumors. Curr Opin Oncol 5: 474-480, 1993
45. Louis DN, Seizinger BR: Genetic basis of neurological tumours. Clin Neurol 3: 335-352, 1994
46. Daumas-Duport C: Histological grading of gliomas. Curr Opin Neurol Neurosurg 5: 924-931, 1992
47. Kleihues P, Burger PC, Scheithauer BW: Histological Typing of Tumours of the Central Nervous System. 2nd edition, Springer, Berlin Heidelberg, 1993
48. Rainov NG, Dobberstein KU, Fittkau M, Bahn H, Holzhausen HJ, Burkert W: Absence of p53-autoantibodies in patients with malignant glioma. Clin Cancer Res 1 (1995) 775-781
49. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Nelson DF, Fischbach AJ, Chang CH, Rotman M, Asbell SO, et al.: Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol 12: 219-227, 1992
50. Nelson DF, Curran WJ Jr, Scott C, Nelson JS, Weinstein AS, Ahmad K, Constine LS, Murray K, Powlis WD, Mohiuddin M, et al.: Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma-possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: Report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys 25: 193-207, 1993
51. Rajan B, Ross G, Lim CC, Ashley S, Goode D, Traish D, Brada M: Survival in patients with recurrent glioma as a measure of treatment efficacy: Prognostic factors following nitrosourea chemotherapy. Eur J Cancer 30A: 1809-1815, 1994
52. Shibamoto Y, Yamashita J, Takahashi M, Yamasaki T, Kikuchi H, Abe M: Supratentorial malignant glioma: An analysis of radiation therapy in 178 cases. Radiother Oncol 18: 9-17, 1990
53. Vecht CJ, Avezaat CJ, van Putten WL, Eijkenboom WM, Stefanko SZ: The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psych 53: 466-471, 1990
54. Ayoubi S, Walter PH, Naik S, Sankaran M, Robinson D: Audit in the management of gliomas. Br J Neurosurg 7: 61-69, 1993
55. Chandler KL, Prados MD, Malec M, Wilson CB: Long-term survival in patients with glioblastoma multiforme. Neurosurgery 32: 716-720, 1993
56. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al.: Recursive partitioning analysis of prognostic factors in three Radiation Therapy O neology Group malignant glioma trials. J Natl Cancer Inst 85: 704-710, 1993
57. Prados MD, Gutin PH, Phillips TL, Wara WM, Larson DA, Sneed PK, Davis RL, Ahn DK, Lamborn K, Wilson CB: Highly anaplastic astrocytoma: A review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 23: 3-8, 1992
58. Stea B, Rossman K, Kittelson J, Shetter A, Hamilton A, Cassady JR: Interstitial irradiation versus interstitial thermoradiotherapy for supratentorial malignant gliomas: A comparative survival analysis. Int J Radiat Oncol Biol Phys 30: 591-600, 1994
59. Sugawara T, Nakazawa M, Mizutani Y, Hyodoh H: Accelerated hyperfractionation in the treatment of malignant glioma [In Japanese]. Nippon Igaku Hoshasen Gakkai Zasshi 54: 278-285, 1994
60. Brisman R, Housepian EM, Chang C, Duffy P, Balis E: Adjuvant nitrosourea therapy for glioblastoma. Arch Neurol 33: 745-750, 1976
61. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y: Comparison of postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52: 997-1007, 1983
62. Eyre HJ, Quagliana JM, Eltringham JR, Frank J, O'Bryan RM, McDonald B, Rivkin SE: Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malingant gliomas following surgery. J Neurooncol 1: 171-177, 1983
63. Franklin CI: Does the extent of surgery make a difference in high grade malignant astrocytoma? Australas Radiol 36: 44-47, 1992
64. Quigley MR, Maroon JC: The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29: 385-388, 1991
65. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS, et al.: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26: 239-244, 1993
66. Nitta T, Sato K: Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 75: 2727-2731, 1995
67. Hollerhage HG, Zumkeller M, Becker M, Dietz H: Influence of type and extent of surgery on early results and survival time in glioblastoma multiforme. Acta Neurochir 113: 31-37, 1991
68. Sandeman DR, Sandeman AP, Buxton P, Hughes HH, Chadwick DW, Williams IR, Baker RD, Foy PM, Shaw DM: The management of patients with an intrinsic supratentorial brain tumour. Br J Neurosurg 4: 299-312, 1990.
69. Kallio M, Sankila R, Jaaskelainen J, Karjalainen S, Hakulinen T: A population-based study on the incidence and survival rates of 3857 glioma patients diagnosed from 1953 to 1984. Cancer 68: 1394-1400, 1991
70. Yamada S, Takai Y, Nemoto K, Ogawa Y, Kakuto Y, Hoshi A, Sakamoto K, Kayama T, Yoshimoto T: Radioresponse and prognosis of malignant glioma. Tohoku J Exp Med 167: 79-87, 1992
71. Sullivan FJ, Herscher LL, Cook JA, Smith J, Steinberg SM, Epstein AH, Oldfield EH, Goffman TE, Kinsella TJ, Mitchell JB, et al.: National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: Results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 30: 583-590, 1994
72. Yoshida J, Kajita Y, Wakabayashi T, Sugita K: Long-term follow-up results of 175 patients with malignant glioma: Importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir 127: 55-59, 1994
73. Fujiwara T, Honma Y, Ogawa T, Irie K, Kuyama H, Nagao S, Takashima H, Hosokawa A, Ohkawa M, Tanabe M: Intraoperative radiotherapy for gliomas. J Neurooncol 23: 81-86, 1995
74. Levin VA, Prados MR, Wara WM, Davis RL, Gutin PH, Phillips TL, Lamborn K, Wilson CB: Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 32: 75-83, 1995
75. Coffey RJ, Lunsford LD, Flickinger JC: The role of radiosurgery in the treatment of malignant brain tumors. Neurosurg Clin N Am 3: 231-244, 1992
76. Calliauw L, Sieben G: The future of chemotherapy in malignant brain tumors. Neurosurg Rev 9: 27-30, 1986
77. Laramore GE, Martz KL, Nelson JS, Griffin TW, Chang CH, Horton J: Radiation Therapy Oncology Group (RTOG) survival data on anaplastic astrocytomas of the brain: Does a more aggressive form of treatment adversely impact survival? Int J Radiat Oncol Biol Phys 17: 1351-1356, 1989
78. Fischbach AJ, Martz KL, Nelson JS, Griffin TW, Chang CH, Horton J, Nelson DF: Long-term survival in treated anaplastic astrocytomas. A report of combined RTOG/ ECOG studies. Am J Clin Oncol 14: 365-370, 1991
79. Rozental JM, Robins HI, Finlay J, Healey B, Levin AB, Steeves RA, Kohler PC, Schutta HS, Trump DL: Eight-drugs-in-one-day chemotherapy in postirradiated adult patients with malignant gliomas. Med Pediatr Oncol 17: 471-476, 1989
80. Neuwelt EA, Howieson J, Frenkel EP, Specht HD, Weigel R, Buchan CG, Hill SA : Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 19: 573-582, 1986
81. Schold SC Jr, Mahaley MS Jr, Vick NA, Friedman HS, Burger PC, DeLong ER, Albright RE Jr, Bullard DE, Khandekar JD, Cairncross JG, et al.: Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms. J Clin Oncol 5:464-471, 1987
82. Watne K, Hannisdal E, Nome O, Hager B, Hirschberg H: Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy. Acta Oncol 32: 307-310, 1993
83. Petersdorf SH, Livingston RB: High dose chemotherapy for the treatment of malignant brain tumors. J Neurooncol 20: 155-163, 1994
84. Leibel SA, Scott CB, Loeffler JS: Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol 21: 198-219, 1994
85. Chung R, Whaley J, Kley N, Anderson K, Louis D, Menon A, Hettlich C, Freiman R, Hedley-White ET, Martuza R, et al.: TP53 Gene mutations and 17p deletions in human astrocytomas. Genes Chromosom Cancer 3: 323-331, 1991
86. Louis DN, von Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, Seizinger BR : Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31-38, 1993
87. Frankel RH, Bayona W, Koslow M, Newcomb EW: p53 Mutations in human malignant gliomas: Comparison of loss of heterozygosity with mutation frequency. Cancer Res 52:1427-1433, 1992
88. Finlay CA : The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301-306, 1993
89. Sarraj S, Bridges LR: p53 Immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 9: 143-149, 1995
90. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828-4831, 1992
91. Karamitopoulou E, Perentes E, Diamantis I: p53 Protein expression in central nervous system tumors: An immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol 85: 611-616, 1993
92. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW: High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9: 949-954, 1994
93. Bruner JM, Saya H, Moser RP: Immunocytochemical detection of p53 in human gliomas. Modern Pathol 4: 671-674, 1991
94. Ali IU, Schweitzer JB, Ikejiri B, Saxena A, Robertson JT, Oldfield EH: Heterogeneity of subcellular localization of p53 protein in human glioblastomas. Cancer Res 54: 1-5, 1994
95. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC: A comparative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3: 229-235, 1993
96. Louis DN: p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53: 11-21, 1994
97. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846-847, 1992
98. Koga H, Zhang S, Kumanishi T, Washiyama K, Ichikawa T, Tanaka R, Mukawa J: Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 87: 225-232, 1994
99. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K: Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 6: 1313-1318, 1991
100. Ng HK, Lo SY, Huang DP, Poon WS: Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. Pathology 26: 1-5, 1994
101. Bruner JM: Neuropathology of malignant gliomas. Semin Oncol 21: 126-138, 1994
102. Soini Y, Niemela A, Kamel D, Herva R, Bloigu R, Paakko P, Vahakangas K: p53 Immunohistochemical positivity as a prognostic marker in intracranial tumours. APMIS 102: 786-792, 1994
103. Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH: Abberant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery 37: 246-254, 1995
104. He J, Reifenberger G, Liu L, Collins VP, James CD : Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosom Cancer 11: 91-96, 1994
105. Hunter SB, Abbott K, Varma VA, Olson JJ, Barnett DW, James CD Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J Neuropathol Exp Neurol 54: 57-64, 1995
106. Kondo S, Barnett GH, Hara H, Morimura T, Takeuchi J: MDM2 Protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10: 2001-2006, 1995
107. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992
108. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698, 1995
109. Mccann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, Dervan PA : Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 71: 981-985, 1995
110. Bueso-Ramos CE, Manshouri T, Haidar MA, Huh YO, Keating MJ, Albitar M: Multiple patterns of MDM-2 deregulation in human leukemias: Implications in leukemogenesis and prognosis. Leuk Lymphoma 17: 13-18, 1995
111. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU: Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52: 4550-4553, 1992
112. Hoi-Sang U, Espiritu OD, Kelley PY, Klauber MR, Hatton JD: The role of the epidermal growth factor receptor in human gliomas: I. The control of cell growth. J Neurosurg 82: 841-846, 1995
113. Hoi-Sang U, Espiritu OD, Kelley PY, Klauber MR, Hatton JD: The role of the epidermal growth factor receptor in human gliomas: II. The control of glial process extension and the expression of glial fibrillary acidic protein. J Neurosurg 82: 847-857, 1995
114. Reifenberger G, Prior R, Deckert M, Wechsler W: Epidermal growth factor receptor expression and growth fraction in human tumours of the nervous system. Virch Arch A Pathol Anat Histopathol 414: 147-155, 1989
115. Hiesiger EM, Hayes RL, Pierz DM, Budzilovich GN : Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol 16: 93-104, 1993
116. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J: Amplification of epidermal growth factor receptor gene in gliomas: Histopathology and prognosis. J Neuropathol Exp Neurol 51: 84-90, 1992
117. Pigott TJ, Robson DK, Palmer J, Ward LM: Expression of epidermal growth factor receptor in human glioblastoma multiforme. Br J Neurosurg 7: 261-265, 1993
118. Dorward NL, Hawkins RA, Whittle IR : Epidermal growth factor receptor activity and clinical outcome in glioblastoma and meningioma. Br J Neurosurg 7: 197-199, 1993